What is the 13F Pro Quality Score for AMGN?

13F Pro ranks AMGEN INC (AMGN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View AMGN's current score at https://13fpro.ai/research/AMGN (free sign-up required for the full ranking).

Which hedge funds own the most AMGN stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of AMGN include BlackRock,, VANGUARD CAPITAL MANAGEMENT, STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/AMGN as soon as new 13F filings post.

Where does 13F Pro source AMGN data?

All AMGEN INC fundamentals and ownership data come directly from SEC EDGAR. AMGEN INC files with the SEC under CIK 318154. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is AMGN in?

AMGEN INC (AMGN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives AMGN's revenue?

Per AMGEN INC's latest 10-Q filed with the SEC on 2026-05-01, the biggest revenue drivers are: Product Sales ($8.2B, +4% YoY); Other Revenues ($400M, +45% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/research/AMGN.

What are AMGN's largest expenses?

AMGEN INC's latest 10-Q reports these as the largest expense items: Cost of Sales ($2.7B, -8% YoY); Research and Development ($1.7B, +16% YoY); Selling, General and Administrative ($1.6B, -5% YoY). Sourced directly from SEC EDGAR filing text for Q1 2026 (quarter ended March 31, 2026).

How often is AMGN research updated on 13F Pro?

AMGN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

AMGEN INC(AMGN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 318154 AMGN stock profile & AI dashboard →

13F Pro Quality Score

79.5/100

Rank #53 of 2,879 stocksTOP 5%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

72.7/100

Profitability

89.1/100

Balance Sheet

84.8/100

Earnings Quality

66.7/100

Free Cash Flow

81.8/100

Institutional Flow

38.1/100

Revenue Scale

96.0/100

Dilution Risk

49.4/100

AMGN Stock Analysis & AI Quality Score

AI stock analysis and institutional research for AMGEN INC (AMGN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AMGN at 79.5/100 on a 32-signal composite quality model, placing it at rank #53 of 2,879 stocks — the top 5% of the AI-ranked universe. AMGN scores in the top quartile across revenue scale (96.0), profitability (89.1), balance sheet strength (84.8). Areas of concern include institutional flow (38.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 49.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), AMGEN INC reports quarterly revenue of $8.6B, net income of $1.8B, an operating margin of 30.9%. Top institutional holders of AMGN by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. AMGN trades on the Nasdaq exchange and files with the SEC under CIK 318154. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AMGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AMGEN INC directly from SEC EDGAR. AMGEN INC's 13F Pro composite quality score has ranged between 64 and 86 since 2021, currently 79.5 — a stable long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about AMGEN INC

Quirks, history, and lore behind AMGN — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · mega-cap · listed on Nasdaq · headquartered in Southern California.
2
The Numbers
Annual revenue around $33 billion, with a fat profit margin north of 25% — this is not a company that sells aspirin at Walgreens.
3
The History
Founded in 1980 as one of the first-ever biotechnology companies, it pioneered turning living cells into blockbuster medicines instead of old-school chemistry.
4
The Secret
Its early success was built on drugs that help the body make red blood cells and fight infections after chemotherapy — not glamorous, but worth billions.
5
The Lore
Its hit drug Enbrel — for rheumatoid arthritis — was once among the best-selling drugs on Earth, and the company has long been the quiet giant that other biotech firms dream of becoming.
6
The Giveaway
The granddaddy of Thousand Oaks biotech, its name is a mashup of "applied molecular genetics" — and yes, that's basically their whole elevator pitch since 1980.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving AMGN's Business? Latest 10-Q Breakdown

AI-extracted from AMGEN INC's 10-Q filed 2026-05-01 — Q1 2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Total revenues rose 6% YoY to $8.6B driven by 4% product sales growth and 45% other revenue increase, while operating income surged 126% to $2.7B due to absence of prior-year Otezla impairment charge.

Biggest Revenue Drivers

Total revenue: $8.6B+6% YoY

Product Sales$8.2B+4% YoY

Volume growth of 9% partially offset by 2% net selling price decline and 2% lower inventory.

Other Revenues$400M+45% YoY

Higher corporate partner revenue and royalty income.

Largest Expense Items

Cost of Sales$2.7B-8% YoY

Lower amortization expense from acquisition-related assets, partially offset by higher profit share and royalty expense.

Research and Development$1.7B+16% YoY

Higher spend in Later-Stage Clinical Programs, including MariTide.

Selling, General and Administrative$1.6B-5% YoY

Lower general and administrative expenses, partially offset by higher commercial product-related expenses.

Watch Items from the Filing

TAVNEOS regulatory risk: FDA issued Drug Safety Communication on March 31, 2026 regarding serious liver injury cases (including fatal); on April 27, 2026, FDA proposed withdrawal of approval. Product carrying value of $2.4B at risk; Company continues to engage with FDA.
Prolia/XGEVA biosimilar competition: Patents for RANKL antibodies expired February 2025 (US) and November 2025 (select Europe); multiple biosimilars have launched; Prolia sales down 34% YoY, XGEVA down 27% YoY.
Medicare price setting impact: ENBREL sales declined 37% YoY due to CMS-set Medicare Part D price effective January 1, 2026; Otezla selected for similar treatment effective January 2027; additional products may be selected.
IRS tax dispute: Two consolidated U.S. Tax Court cases for years 2010–2015 seek approximately $8.7B in additional federal tax plus interest and penalties; trial concluded January 2025; decision expected no earlier than H2 2026. Draft NOPA for 2016–2018 also received in April 2026.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q1 2026

$8.6B

Net Income

Q1 2026

$1.8B

Free Cash Flow

Q1 2026

$1.5B

Operating Margin

Q1 2026

30.9%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+10.0% YoY

$36.75BFY 2025

FY22 $26.32BFY23 $28.19BFY24 $33.42BFY25 $36.75B

Net Income

+88.5% YoY

$7.71BFY 2025

FY22 $6.55BFY23 $6.72BFY24 $4.09BFY25 $7.71B

Operating Income

+25.1% YoY

$9.08BFY 2025

FY22 $9.57BFY23 $7.90BFY24 $7.26BFY25 $9.08B

EPS (Diluted)

+88.2% YoY

$14.23FY 2025

FY22 $12.11FY23 $12.49FY24 $7.56FY25 $14.23

Total Assets

-1.4% YoY

$90.59BFY 2025

FY22 $65.12BFY23 $97.15BFY24 $91.84BFY25 $90.59B

Total Debt

-7.0% YoY

$59.20BFY 2025

FY22 $40.54BFY23 $66.06BFY24 $63.65BFY25 $59.20B

Op. Cash Flow

-13.3% YoY

$9.96BFY 2025

FY22 $9.72BFY23 $8.47BFY24 $11.49BFY25 $9.96B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$36.75B +10.0%	$33.42B +18.6%	$28.19B +7.1%	$26.32B +1.3%	$25.98B +2.2%	$25.42B
Net Income	$7.71B +88.5%	$4.09B -39.1%	$6.72B +2.5%	$6.55B +11.2%	$5.89B -18.9%	$7.26B
Operating Income	$9.08B +25.1%	$7.26B -8.1%	$7.90B -17.4%	$9.57B +25.2%	$7.64B -16.4%	$9.14B
EPS (Diluted)	$14.23 +88.2%	$7.56 -39.5%	$12.49 +3.1%	$12.11 +17.8%	$10.28 -16.5%	$12.31
Total Assets	$90.59B -1.4%	$91.84B -5.5%	$97.15B +49.2%	$65.12B +6.5%	$61.16B -2.8%	$62.95B
Total Debt	$59.20B -7.0%	$63.65B -3.6%	$66.06B +63.0%	$40.54B +21.4%	$33.40B +1.0%	$33.08B
Operating Cash Flow	$9.96B -13.3%	$11.49B +35.6%	$8.47B -12.9%	$9.72B +5.0%	$9.26B -11.8%	$10.50B

AI Insight: AMGN Financial Trends

Amgen grew revenue 2.7% year-over-year to $8.6B in Q1 2026 while reducing net debt by $5.4B since Q2 2024, but operating cash flow remains volatile.

• Revenue expanded from $8,149M (Q1 2025) to $8,618M (Q1 2026), +5.7% YoY.

• Total debt fell 8.2% from $68,173M (Q2 2024) to $62,760M (Q1 2026), strengthening balance sheet.

• Operating margin improved to 30.9% (Q1 2026) vs. 14.5% (Q1 2025), despite lower absolute op income.

⚠ Operating cash flow declined 53% to $2,189M in Q1 2026 from $4,684M in Q3 2025 — sharp pullback.

⚠ Net income volatility persists: $1,819M (Q1 2026) vs. $3,216M (Q3 2025), suggesting earnings lumpy.

AI Insight: AMGN Ratio Trends

Operating margin surged to 30.9% in Q1 2026, highest on record, while debt-to-equity stabilized near 6.8x after multi-quarter deleveraging.

• Operating margin expanded from 14.5% in Q1 2025 to 30.9% in Q1 2026, a 16.4pp surge reflecting operational leverage recovery.

• Debt-to-equity improved from 11.51x in Q2 2024 to 6.83x in Q1 2026, demonstrating sustained balance-sheet strengthening.

• ROIC recovered to 14.8% (TTM) from a low of 7.0% in Q1 2025, approaching prior-year highs of 16.1%.

⚠ Net profit margin volatility persists: swung from 33.7% (Q3 2025) to 13.5% (Q4 2025) to 21.1% (Q1 2026)—monitor earnings stability.

⚠ ROE declined to 79.2% in Q1 2026 from 133.7% in Q3 2025; assess whether reflects normalized earnings or underlying headwinds.

Get alerted when AMGN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for AMGEN INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of AMGN

BlackRock, Inc.
$16.6B47,100,472 sh
VANGUARD CAPITAL MANAGEMENT LLC
$12.3B35,014,232 sh
STATE STREET CORP
$10.7B30,548,488 sh
Capital World Investors
$10.3B29,288,343 sh
MORGAN STANLEY
$5.6B15,836,058 sh
GEODE CAPITAL MANAGEMENT, LLC
$5.4B15,430,524 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$5.1B14,621,148 sh
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
$4.5B12,773,386 sh
PRIMECAP MANAGEMENT CO/CA/
$3.1B8,874,129 sh
Capital International Investors
$2.5B7,122,275 sh

Fund	Value	Shares
BlackRock, Inc.	$16.6B	47,100,472
VANGUARD CAPITAL MANAGEMENT LLC	$12.3B	35,014,232
STATE STREET CORP	$10.7B	30,548,488
Capital World Investors	$10.3B	29,288,343
MORGAN STANLEY	$5.6B	15,836,058
GEODE CAPITAL MANAGEMENT, LLC	$5.4B	15,430,524
VANGUARD PORTFOLIO MANAGEMENT LLC	$5.1B	14,621,148
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	$4.5B	12,773,386
PRIMECAP MANAGEMENT CO/CA/	$3.1B	8,874,129
Capital International Investors	$2.5B	7,122,275

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put AMGN on your watchlist

Track score changes the day AMGEN INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is AMGN a good stock to buy?

13F Pro's AI-powered analysis of AMGEN INC (AMGN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AMGN are available on the AMGN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own AMGN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AMGN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of AMGEN INC's investment landscape.